Security Snapshot

Dogwood Therapeutics, Inc. - Common Stock, par value $0.0001 (DWTX) Institutional Ownership

CUSIP: 92829J203

13F Institutional Holders and Ownership History from Q4 2024 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

16

Shares (Excl. Options)

3,829,726

Price

$1.61

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+209,958
Value change
+$324,861
Number of holders
16
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
33,881,862
SEC-reported price per share
$1.61
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • DWTX - Dogwood Therapeutics, Inc. - Common Stock, par value $0.0001 is tracked under CUSIP 92829J203.
  • 16 institutions reported positions in Q2 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 13 to 16 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $7,637,717 to $6,165,867.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 16 institutions filings for Q2 2026.

Open SEC evidence

Security key

92829J203

Latest holder period

Q2 2026

13F holders

16

13D/G owners

3

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
DWTX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sealbond Ltd 83% +419% $164,022,057 +$162,616,360 24,664,971 +11568% CK Life Sciences Int'l., (Holdings) Inc. 21 Nov 2025
ARMISTICE CAPITAL, LLC 10% 0% $5,446,817 +$67,068 3,384,798 +1.2% Armistice Capital, LLC 30 Jun 2026
Orca Capital AG 3.7% -40% $390,299 -$256,967 69,821 -40% Orca Capital AG 14 Mar 2025

As of 30 Jun 2026, 16 institutional investors reported holding 3,829,726 shares of Dogwood Therapeutics, Inc. - Common Stock, par value $0.0001 (DWTX). This represents 11% of the company’s total 33,881,862 outstanding shares.

13F concentration

Top 18 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
11%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARMISTICE CAPITAL, LLC 9.2% 3,132,486 -4.5% 0.14% $5,043,302
MILLENNIUM MANAGEMENT LLC 1% 341,814 0% $550,321
VANGUARD CAPITAL MANAGEMENT LLC 0.39% 132,154 0% 0% $212,768
GEODE CAPITAL MANAGEMENT, LLC 0.26% 88,298 +11% 0% $142,161
VANGUARD FIDUCIARY TRUST CO 0.19% 62,736 0% 0% $101,005
BlackRock, Inc. 0.08% 28,546 +95053% 0% $45,959
NORTHERN TRUST CORP 0.07% 23,779 0% 0% $38,284
CITADEL ADVISORS LLC 0.03% 11,742 0% $18,905
Tower Research Capital LLC (TRC) 0.01% 3,093 -62% 0% $4,980
MORGAN STANLEY 0.01% 2,222 0% $3,577
UBS Group AG 0.01% 1,860 -74% 0% $2,995
MERCER GLOBAL ADVISORS INC /ADV 0% 550 0% $886
JONES FINANCIAL COMPANIES LLLP 0% 160 0% $264
BARCLAYS PLC 0% 157 0% $253
Activest Wealth Management 0% 120 0% 0% $193
GROUP ONE TRADING LLC 0% 9 0% 0% $14
MARSHALL WACE, LLP 0% 0 -100% $0
GOLDMAN SACHS GROUP INC 0% 0 -100% $0

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
7
Latest
Q2 2026
Rows shown
1-7 of 7
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 3,829,726 $6,165,867 +$324,861 $1.61 16
2026 Q1 3,619,770 $7,637,717 +$7,121,325 $2.11 13
2025 Q4 70,190 $291,995 +$127,207 $4.16 10
2025 Q3 38,897 $299,516 -$33,184 $7.70 12
2025 Q2 43,200 $207,544 -$197,053 $4.77 10
2025 Q1 81,969 $409,793 +$256,592 $5.01 13
2024 Q4 30,770 $76,511 +$76,491 $2.49 10
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .